Premium
Aptamer‐integrated α‐Gal liposomes as bispecific agents to trigger immune response for killing tumor cells
Author(s) -
Hong Shanni,
Ding Pi,
Luo Yu,
Gao Tian,
Zhang Ye,
Pei Renjun
Publication year - 2019
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.36609
Subject(s) - aptamer , nucleolin , liposome , materials science , immune system , cytotoxicity , microbiology and biotechnology , lysis , biology , biophysics , biochemistry , nanotechnology , immunology , in vitro , cytoplasm , nucleolus
A novel bispecific α‐Gal liposome was constructed by self‐assembling AS1411 aptamers into the α‐Gal containing liposomes. The α‐Gal liposomes were prepared using cell membranes of red blood cells from rabbit, which are composed of cholesterol, phospholipids, and α‐Gal glycolipids. AS1411 is a DNA aptamer with high specificity and affinity for nucleolin and could integrate into liposomes by the modification of cholesterol. The bispecific α‐Gal liposomes surface‐functionalized by α‐Gal and AS1411 aptamer could recognize anti‐Gal antibodies and nucleolin overexpressed by tumor cells simultaneously, followed by activating the immune system to attack the tumor cells, resulting in the lysis of the tumor cells by antibody dependent cell‐mediated cytotoxicity. Under simulated tumor environment, the lysis rate of MCF‐7 cells treated by the AS1411 modified α‐Gal liposomes drastically increased compared to the liposomes without AS1411 aptamer. This study suggests that the AS1411 modified α‐Gal liposomes can recognize nucleolin‐overexpressing tumor cells selectively, subsequently improve the effect of the immunotherapy with high specificity. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 107A: 1176–1183, 2019.